We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
You will need to install the app on your new mobile device and pair it with your smart transmitter. The
last 3 days of glucose data will be synced to the app on the new mobile device.
Download our discussion guide and bring it to your next appointment and talk to your doctor about how Eversense 365 may be a better fit for your diabetes management plan. We will work with you and your health care provider to manage your insurance claim.
Initialization Phase (after 24-hour Warm-Up Phase)
During the Initialization Phase, four (4) finger stick blood glucose meter tests are required for calibration.
The 4 calibration tests must be spaced 2 to 12 hours apart, and all 4 tests must be completed within a 36 hour period.
– 1st calibration = 24 hours after sensor insertion.
– 2nd calibration = 2 to 12 hours after 1st successful calibration.
– 3rd calibration = 2 to 12 hours after 2nd successful calibration.
– 4th calibration = 2 to 12 hours after 3rd successful calibration.
Glucose readings will start displaying in the app a few minutes after the 2nd calibration is successfully completed.
DO NOT use the Eversense® Apps on jailbroken or rooted devices.
Jailbroken devices do not provide an acceptable level of security and accuracy for the user, and are not approved for use by Senseonics
While it is possible, in the Eversense E3 pivotal clinical trial (PROMISE Study), most users were in 1 calibration/day 62% of the time and in 2 calibrations a day 38% of the time, after day 21.
The simple answer is no. While you may optionally calibrate the Eversense E3 System more frequently, (daily calibrations entries must be spaced at least one hour apart), this will not impact the accuracy of the system.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
MKT-001692 Rev 1